Omentin-1 vs Teduglutide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Teduglutide (Teduglutide (glycyl-2 human glucagon-like peptide-2 analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Teduglutide |
|---|---|---|
| Category | Diabetes & Metabolic | Gastrointestinal |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Teduglutide (glycyl-2 human glucagon-like peptide-2 analog) |
| Molecular Weight | ~35 kDa | 3752 Da |
| Half-Life | hours | approximately 2-3 hours |
| Amino Acids | 313 | 33 |
| Typical Dose | No approved human dose; research use only | 0.05 mg/kg/day |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 300 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Teduglutide Benefits
- ✓mucosal-growth
- ✓absorption-support
- ✓barrier-repair
- ✓intestinal-adaptation
Omentin-1 Dosing
not established|not established
Teduglutide Dosing
0.05 mg/kg once daily subcutaneous injection|chronic maintenance dosing in approved use|monitor fluid status and intestinal anatomy
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Teduglutide Side Effects
- ⚠abdominal pain
- ⚠fluid retention
- ⚠polyp/neoplasia monitoring needed
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Teduglutide
Teduglutide has robust clinical evidence showing improved intestinal absorption and reduced parenteral nutrition dependence in short bowel syndrome. Its mechanism, via GLP-2 receptor activation, makes it highly relevant to mucosal healing and intestinal adaptation research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.